Carboplatin/gemcitabine combination in advanced NSCLC.

Sakkaraiappan Ramalingam, Chandra Belani

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

The treatment of advanced non-small-cell lung cancer (NSCLC) has evolved rapidly over the past few years. Systemic chemotherapy is associated with both quality of life and modest survival benefit for patients with advanced NSCLC. Platinum-based doublet combinations are the "standard of care." The US Food and Drug Administration (FDA) has approved gemcitabine (Gemzar), a pyrimidine analog, to be used in combination with cisplatin for the treatment of advanced NSCLC in the first-line setting. Randomized clinical trials have established comparable efficacy with improved therapeutic index for the carboplatin/gemcitabine regimen when compared with cisplatin/gemcitabine and other platinum doublets. Nonhematologic toxicities occur at a lower frequency with carboplatin/gemcitabine combinations compared with other "standard" platinum-based doublets, whereas dose-limiting thrombocytopenia, the most common toxicity, rarely requires therapeutic intervention. Both the 3- and 4-week schedules of carboplatin/gemcitabine result in similar efficacy and toxicity profiles, but the 3-week regimen is preferred. The combination of carboplatin and gemcitabine is an effective regimen with an acceptable toxicity profile for the treatment of advanced NSCLC. This regimen can also be used as a foundation for the development of innovative combinations with molecularly targeted agents.

Original languageEnglish (US)
Pages (from-to)21-26
Number of pages6
JournalOncology
Volume18
Issue number8 Suppl 5
StatePublished - Jul 2004

Fingerprint

gemcitabine
Carboplatin
Non-Small Cell Lung Carcinoma
Platinum
Cisplatin
Therapeutics
United States Food and Drug Administration
Standard of Care
Thrombocytopenia
Appointments and Schedules
Randomized Controlled Trials
Quality of Life

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Ramalingam, Sakkaraiappan ; Belani, Chandra. / Carboplatin/gemcitabine combination in advanced NSCLC. In: Oncology. 2004 ; Vol. 18, No. 8 Suppl 5. pp. 21-26.
@article{23767686244d4145b2bcece090956c15,
title = "Carboplatin/gemcitabine combination in advanced NSCLC.",
abstract = "The treatment of advanced non-small-cell lung cancer (NSCLC) has evolved rapidly over the past few years. Systemic chemotherapy is associated with both quality of life and modest survival benefit for patients with advanced NSCLC. Platinum-based doublet combinations are the {"}standard of care.{"} The US Food and Drug Administration (FDA) has approved gemcitabine (Gemzar), a pyrimidine analog, to be used in combination with cisplatin for the treatment of advanced NSCLC in the first-line setting. Randomized clinical trials have established comparable efficacy with improved therapeutic index for the carboplatin/gemcitabine regimen when compared with cisplatin/gemcitabine and other platinum doublets. Nonhematologic toxicities occur at a lower frequency with carboplatin/gemcitabine combinations compared with other {"}standard{"} platinum-based doublets, whereas dose-limiting thrombocytopenia, the most common toxicity, rarely requires therapeutic intervention. Both the 3- and 4-week schedules of carboplatin/gemcitabine result in similar efficacy and toxicity profiles, but the 3-week regimen is preferred. The combination of carboplatin and gemcitabine is an effective regimen with an acceptable toxicity profile for the treatment of advanced NSCLC. This regimen can also be used as a foundation for the development of innovative combinations with molecularly targeted agents.",
author = "Sakkaraiappan Ramalingam and Chandra Belani",
year = "2004",
month = "7",
language = "English (US)",
volume = "18",
pages = "21--26",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "8 Suppl 5",

}

Ramalingam, S & Belani, C 2004, 'Carboplatin/gemcitabine combination in advanced NSCLC.', Oncology, vol. 18, no. 8 Suppl 5, pp. 21-26.

Carboplatin/gemcitabine combination in advanced NSCLC. / Ramalingam, Sakkaraiappan; Belani, Chandra.

In: Oncology, Vol. 18, No. 8 Suppl 5, 07.2004, p. 21-26.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Carboplatin/gemcitabine combination in advanced NSCLC.

AU - Ramalingam, Sakkaraiappan

AU - Belani, Chandra

PY - 2004/7

Y1 - 2004/7

N2 - The treatment of advanced non-small-cell lung cancer (NSCLC) has evolved rapidly over the past few years. Systemic chemotherapy is associated with both quality of life and modest survival benefit for patients with advanced NSCLC. Platinum-based doublet combinations are the "standard of care." The US Food and Drug Administration (FDA) has approved gemcitabine (Gemzar), a pyrimidine analog, to be used in combination with cisplatin for the treatment of advanced NSCLC in the first-line setting. Randomized clinical trials have established comparable efficacy with improved therapeutic index for the carboplatin/gemcitabine regimen when compared with cisplatin/gemcitabine and other platinum doublets. Nonhematologic toxicities occur at a lower frequency with carboplatin/gemcitabine combinations compared with other "standard" platinum-based doublets, whereas dose-limiting thrombocytopenia, the most common toxicity, rarely requires therapeutic intervention. Both the 3- and 4-week schedules of carboplatin/gemcitabine result in similar efficacy and toxicity profiles, but the 3-week regimen is preferred. The combination of carboplatin and gemcitabine is an effective regimen with an acceptable toxicity profile for the treatment of advanced NSCLC. This regimen can also be used as a foundation for the development of innovative combinations with molecularly targeted agents.

AB - The treatment of advanced non-small-cell lung cancer (NSCLC) has evolved rapidly over the past few years. Systemic chemotherapy is associated with both quality of life and modest survival benefit for patients with advanced NSCLC. Platinum-based doublet combinations are the "standard of care." The US Food and Drug Administration (FDA) has approved gemcitabine (Gemzar), a pyrimidine analog, to be used in combination with cisplatin for the treatment of advanced NSCLC in the first-line setting. Randomized clinical trials have established comparable efficacy with improved therapeutic index for the carboplatin/gemcitabine regimen when compared with cisplatin/gemcitabine and other platinum doublets. Nonhematologic toxicities occur at a lower frequency with carboplatin/gemcitabine combinations compared with other "standard" platinum-based doublets, whereas dose-limiting thrombocytopenia, the most common toxicity, rarely requires therapeutic intervention. Both the 3- and 4-week schedules of carboplatin/gemcitabine result in similar efficacy and toxicity profiles, but the 3-week regimen is preferred. The combination of carboplatin and gemcitabine is an effective regimen with an acceptable toxicity profile for the treatment of advanced NSCLC. This regimen can also be used as a foundation for the development of innovative combinations with molecularly targeted agents.

UR - http://www.scopus.com/inward/record.url?scp=12744272668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12744272668&partnerID=8YFLogxK

M3 - Review article

C2 - 15339055

AN - SCOPUS:12744272668

VL - 18

SP - 21

EP - 26

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 8 Suppl 5

ER -